DPYD PharmaKitDx – Advancing Personalized Cancer Treatment
DPYD PharmaKitDx is a groundbreaking genetic testing solution designed to identify patients with dihydropyrimidine dehydrogenase (DPD) deficiency, affecting the metabolism of certain cancer chemotherapy drugs.
This test is also available as a Stripassay 5FU DPYD (PGX-5FU XL) from our esteemed partner Viennalab.
Introduction:
DPYD PharmaKitDx is an innovative genetic testing solution that identifies patients with dihydropyrimidine dehydrogenase (DPD) deficiency. DPD is an essential enzyme responsible for metabolizing fluoropyrimidine drugs used in cancer chemotherapy, like 5-fluorouracil (5-FU) and capecitabine.
Understanding DPD Deficiency :
Certain individuals carry genetic variations in the DPYD gene, leading to reduced or absent DPD activity. This condition puts them at a higher risk of severe and potentially life-threatening side effects when receiving standard doses of fluoropyrimidine medications. Early detection of DPD deficiency allows healthcare professionals to tailor treatments and make informed decisions for each patient’s optimal outcomes.
Simple Process for Researchers and Lab Technicians:
Using DPYD PharmaKitDx is straightforward for researchers and lab technicians. The kit provides all necessary materials and detailed instructions to collect a patient’s DNA sample, usually through blood or saliva. Within a short time, the lab delivers comprehensive genetic testing results, indicating the patient’s DPD status. Based on these results, clinicians can customize the treatment plan for maximum safety and efficacy.
The Future of Personalized Medicine:
DPYD PharmaKitDx represents a significant stride towards personalized medicine in oncology. As pharmacogenomics advances, similar genetic testing kits may emerge for other drugs and conditions, further enhancing patient outcomes and improving quality of life.
Specifications:
DPYD*2A Master Mix: specific oligonucleotides, FAM- and VIC-labeled probes, and PCR-grade water for the detection of the DPYD*2A variant.
DPYD*13 Master Mix: specific oligonucleotides, FAM- and VIC-labeled probes, and PCR-grade water for the detection of the DPYD*13 A>C variant.
DPYD*hapB3 Master Mix: specific oligonucleotides, FAM- and VIC-labeled probes, and PCR-grade water for the detection of the IVS10 G>C variant, included in *habB3.
DPYD D949 Master Mix: specific oligonucleotides, FAM- and VIC-labeled probes, and PCR-grade water for the detection of D949V T>A variant.
General Master Mix: PCR master mix with nucleotides, MgCl2, DNA polymerase and buffer required to perform real-time PCR.
Positive Control: synthetic positive control for all study variants.
Goffin Molecular Technologies is a leading Dutch company with a rich history, offering a diverse range of high-quality molecular diagnostics products from various manufacturers.
